The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
Abstract
INTRODUCTION: Clinicians are increasingly challenged by patients with refractory vulvovaginal candidiasis (VVC) caused by azole-resistant Candida species. Fluconazole resistant C.albicans is a growing and perplexing problem following years of indiscriminate drug prescription and unnecessary drug exposure and for which there are few therapeutic alternatives. Regrettably, although the azole class of drugs has expanded, new classes of antifungal drugs have not been forthcoming, limiting effective treatment options in patients with azole resistant Candida vaginitis. AREAS COVERED: This review covers published data on epidemiology, pathophysiology and treatment options for women with azole-resistant refractory VVC. EXPERT OPINION: Fluconazole resistant C.albicans adds to the challenge of azole resistant non-albicans Candida spp. Both issues follow years of indiscriminate drug prescription and unnecessary fluconazole exposure. Although an understanding of azole resistance in yeast has been established, this knowledge has not translated into useful therapeutic advantage. Treatment options for such women with refractory symptoms are extremely limited. New therapeutic options and strategies are urgently needed to meet this challenge of azole drug resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recurrence can also result from developed resistance to antifungal treatment, usually due to prolonged or repeated use of a single agent. 11”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [11]
In the citing paper
“Although breakthrough infections are still relatively rare (usually < 5% of patients), in vitro susceptibility testing can be useful in selecting subsequent treatment.11,18”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [11]
In the citing paper
“Development of azole-resistant infection may be suspected in women who do not respond to standard treatment regimens or who experience breakthrough symptoms despite compliant long-term fluconazole maintenance therapy. 11”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [11]
In the citing paper
“Treating azole-resistant vaginitis constitutes a major clinical challenge for providers, given the current paucity of alternative antimycotic agents. 11”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [11]
In the citing paper
“in vitro susceptibility testing can be useful in selecting subsequent treatment.11,18”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [11]
In the citing paper
“In addition, non-albicans Candida species are frequently dose-dependent susceptible or resistant to fluconazole and other azoles, and their prevalence is rising.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
In the citing paper
“A long-term prophylactic maintenance regimen with antifungals is often necessary.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
In the citing paper
“Available therapeutic options to treat such fluconazole-resistant C. albicans and low susceptibility non-albicans strains are limited.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
In the citing paper
“Many fluconazole-resistant C. albicans strains are also cross-resistant to other azole drugs available for treating VVC.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
In the citing paper
“Fluconazole-resistant C. albicans vaginitis usually represents less than 5% of isolates obtained from women with RVVC (Sobel and Sobel, 2018; Collins et al., 2020).”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
In the citing paper
“Treatment with first- or second-generation azoles for C glabrata infection is usually unsuccessful, and local nystatin, ciclopiroxolamine, or boric acid is recommended (Sobel and Sobel, 2018).”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
Citations
Cites
J Antimicrob Chemother 1994; 33: 350–351
O’Shaughnessy, E. M., & DAS, S. S. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.350 · Cited by 3,758
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Self-citationResistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 880
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
Global burden of recurrent vulvovaginal candidiasis: a systematic review
Denning, D. W., Kneale, M., Sobel, J. D., & Rautemaa-Richardson, R. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30103-8 · Cited by 639
Self-citationWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Recurrent vulvovaginal candidiasis
Sobel, J. D. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.06.067 · Cited by 502
Self-citationMaintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033114 · Cited by 487
Self-citation
Research works printed but not linked: 8
- Denning D, 2018, Lancet Infect Dis
- Kalaiarasan K, 2017, J Clin Diagn Res, 11, DC06
- Pappas PG, 2016, Clin Infect Dis, 62(4):e1-50
- Patel PK, 2012, AIDS Res Treat, 2012, 262471
- Clark-Ordóñez I, 2017, Med Mycol
- Sanglard D, 2016, Front Med (Lausanne), 15, 11
- De Seta F, 2009, J Antimicrob Chemother
- White DJ, 1993, Genitourin Med, 69, 112
Cited by
Sorted by citations
Vulvovaginal Candidiasis: A Current Understanding and Burning Questions
Willems, H. M. E., Ahmed, S. S., Liu, J., Xu, Z., & Peters, B. M. (2020) · Journal of Fungi · doi:10.3390/jof6010027 · Cited by 357
Role of Vaginal Microbiota Dysbiosis in Gynecological Diseases and the Potential Interventions
Han, Y., Liu, Z., & Chen, T. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.643422 · Cited by 144
Vaginitis in Nonpregnant Patients
(2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003604 · Cited by 103
Martens, M. G., Maximos, B., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., Flynt, A., & Brand, S. R. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.07.023 · Cited by 86
Oteseconazole: An Advance in Treatment of Recurrent Vulvovaginal Candidiasis
Sobel, J. D., & Nyirjesy, P. (2021) · Future Microbiology · doi:10.2217/fmb-2021-0173 · Cited by 78
Self-citation
Metadata
- Authors
- Sobel, J. D., & Sobel, R.
- Affiliations
- Wayne State University (US)
- Thomas Jefferson University Hospital (US)
- Corresponding author
- Sobel, J. D.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2018-06-13
- Volume
- 19
- Issue
- 9
- Pages
- 971-977
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2809133082
- Cited by
- 168
- References
- 56
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 24 · 2023: 39 · 2022: 34 · 2021: 20 · 2020: 13 · 2019: 7 · 2018: 1
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- not funded
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- vaginal candidiasis, azole resistance, Candida albicans, fluconazole resistance, non-albicans Candida, antifungal resistance, Candida vaginitis
- MeSH terms
- Antifungal Agents, Boric Acids, Candida, Candidiasis, Vulvovaginal, Female, Humans, Microbial Sensitivity Tests, Fluconazole, Drug Resistance, Fungal, 14-alpha Demethylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
